NBRV Nabriva Therapeutics plc

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia; and SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI). It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.

Nabriva Therapeutics plc

Peers

Recent Analyst Ratings for Nabriva Therapeutics plc

Nabriva Therapeutics plc Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Northland Securities reiterated coverage on Nabriva Therapeutics with a new price target

Nabriva Therapeutics plc Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 3 filed by new insider Hogan H Michael Iii

SEC Form 3 filed by new insider Maggio David

SEC Form 4: Gelone Steven P. covered exercise/tax liability with 140 units of Ordinary Shares, decreasing direct ownership by 0.97% to 14,283 units to cover taxes

SEC Form 4: Schroeder Theodore R covered exercise/tax liability with 431 units of Ordinary Shares, decreasing direct ownership by 3% to 11,989 units to satisfy tax liability

SEC Form 4: Gelone Steven P. covered exercise/tax liability with 5 units of Ordinary Shares, decreasing direct ownership by 0.03% to 14,423 units (for withholding tax)

SEC Form 4: Schroeder Theodore R covered exercise/tax liability with 11 units of Ordinary Shares, decreasing direct ownership by 0.09% to 12,420 units to satisfy withholding obligation

SEC Form 4: Schroeder Theodore R covered exercise/tax liability with 5 units of Ordinary Shares, decreasing direct ownership by 0.04% to 12,431 units (for tax liability)

SEC Form 4: Gelone Steven P. covered exercise/tax liability with 3 units of Ordinary Shares, decreasing direct ownership by 0.02% to 14,428 units (tax liability)

SEC Form 4: Gelone Steven P. covered exercise/tax liability with 4 units of Ordinary Shares, decreasing direct ownership by 0.03% to 14,431 units to cover taxes

SEC Form 4: Schroeder Theodore R covered exercise/tax liability with 9 units of Ordinary Shares, decreasing direct ownership by 0.07% to 12,436 units (for tax liability)

Nabriva Therapeutics plc SEC Filings

SEC Form 15-12G filed by Nabriva Therapeutics plc

SEC Form EFFECT filed by Nabriva Therapeutics plc

SEC Form S-8 POS filed by Nabriva Therapeutics plc

SEC Form S-8 POS filed by Nabriva Therapeutics plc

SEC Form S-8 POS filed by Nabriva Therapeutics plc

SEC Form S-8 POS filed by Nabriva Therapeutics plc

SEC Form POS AM filed by Nabriva Therapeutics plc

SEC Form S-8 POS filed by Nabriva Therapeutics plc

SEC Form S-8 POS filed by Nabriva Therapeutics plc

SEC Form S-8 POS filed by Nabriva Therapeutics plc